Sponsor or institution
Clinical trials and research at Climb Bio, Inc.
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Climb Bio, Inc. that are recruiting, at sites in 14 countries (most in Ukraine (3), Bulgaria (2), Georgia (2)). By phase: Phase 1 (2), Phase 1/2 (2), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 14Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Budoprutug in systemic lupus erythematosus (SLE) | Phase 1/2 | Mianyang, Sichuan and 9 other locations | Recruiting | May 4, 2026 |
| CLYM116 in healthy adults | Phase 1 | Brisbane | Recruiting | Nov 25, 2025 |
| Budoprutug for primary membranous nephropathy (Phase 2) | Phase 2 | Denver, Colorado and 37 other locations | Recruiting | Jul 31, 2025 |
| Budoprutug for adults with immune thrombocytopenia (ITP) | Phase 1/2 | Plovdiv and 19 other locations | Recruiting | Jun 29, 2025 |
| Budoprutug infusion for adults with active, seropositive lupus | Phase 1 | Allen, Texas and 17 other locations | Recruiting | Jun 8, 2025 |
All recruiting trials (5)
-
Budoprutug in systemic lupus erythematosus (SLE)
A phase 1b/2a study in adults with active SLE will test two-dose levels of Budoprutug given by two IV infusions 14 days apart to see if it lowers B cells and improves disease activity in people who haven’t fully responded to standard therapy.
-
CLYM116 in healthy adults
Researchers will test a new antibody called CLYM116 in healthy adults to check safety, how the body processes it, and its immune effects.
-
Budoprutug for primary membranous nephropathy (Phase 2)
This trial will test whether budoprutug, an anti-CD19 antibody given by IV, is safe and tolerated and may reduce proteinuria in adults with PLA2R-positive primary membranous nephropathy who still have high protein in their urine despite RAAS blockers.
-
Budoprutug for adults with immune thrombocytopenia (ITP)
This trial will test whether two IV doses of budoprutug are safe and can help raise platelet counts in adults with ITP who still have platelets under 30,000/µL after prior treatment.
-
Budoprutug infusion for adults with active, seropositive lupus
This trial will try one IV infusion of budoprutug to see if it is safe and how it affects B cells and symptoms in adults 18–65 with active, seropositive lupus who haven't responded to standard treatments.
Quick answers
How many clinical trials run by Climb Bio, Inc. are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 14 countries. The most sites are in Ukraine (3 trials), Bulgaria (2 trials), Georgia (2 trials), Greece (2 trials), Spain (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2, Phase 1/2: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.